192 results about "Dose" patented technology

The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.

A composition and method for treating diarrhea in small domestic animals wherein the composition includes an effective amount of kaolin, pectin, at least one probiotic, and a carrier, and the method includes the step of orally administering an effective dosage of the composition to the domestic animals.

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.

The present invention relates to the field of medical technology. More specifically, the present invention relates to a preparation of taxanes for intravenous administration, which consists of two parts: a drug solution and an emulsion. Said drug solution consists of paclitaxel or docetaxel, a pH regulator and a solvent for injection, wherein said solvent for injection is an organic solvent. Said emulsion includes a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When used, the drug solution at the clinical dosage can be added and mixed homogeneously in the emulsion to perform intravenous drip directly; or the drug solution at the clinical dosage can also be firstly added into the emulsion with no less than 5 times volume of the drug solution and then a predetermined amount of normal saline or glucose solution for injection is added to perform intravenous drip. The preparation of the present invention does not contain solubilizer and has advantages of little toxicity, safety, effectiveness, stability and economy. The fat emulsion is also used as a nutritional replenishment, thus achieving a better therapeutic effect. In addition, the normal saline or glucose solution for injection can be used to replace a considerable amount of the emulsion, which makes the preparation, therefore, not only cost-efficient, but also convenient for transportation and storage in practice.

The invention discloses a compound isatic root injection for animals and preparation technology, which is characterized by the following: allocating main medicine, adjunct and dissolvent; choosing the main medicine from isatic root, linbevelin, moroxydine and amantadine hydrochloride; choosing the adjunct from anti-oxidant, metal chelating agent and dissolvent for injection. This invention possesses advanced productive technology and long shelf life.

The invention discloses a method for establishing an animal model with opportunistic infections and chronic wasting diseases, and a traditional Chinese medicinal preparation for treating opportunistic infections and chronic wasting diseases. The traditional Chinese medicinal preparation is prepared by the following components in parts by weight: 100-180 parts of monkhood, 100-180 parts of dry ginger, and 100-160 parts of liquorice. The method has the positive effects that the method for establishing the animal model with opportunistic infections and chronic wasting diseases is found, and the model has high controllability, reliability and repeatability, and is convenient and economical to use; the model syndrome accords with the attack process of opportunistic infections and chronic wasting diseases; the model establishing factor accords with the theory of the Internal Canon of Medicine, and does not relates to causal organisms, so that the testing risks can be reduced, and the organism safety can be guaranteed; the traditional Chinese medicinal preparation obtained by screening has the characteristics of high efficiency, no toxicity, wide medicine sources and the like, is convenient to use and economical, can be used for prolonging the life of patients with opportunistic infections and chronic wasting diseases, improving the living quality of the patients and improving lesion of each tissue, and does not have toxic or side effect when a large dosage is used.

The invention discloses a method for identifying a differential marker of IC50 dose of vitamin C for RAW264.7 and K562 cells by applying 1H NMR technology and metabonomic methodology. The method comprises the following steps: (1) determining the IC50 dosage of vitamin C for RAW264.7 or K562 cells; (2) preparing a cell extract; (3) performing nuclear magnetic resonance pretreatment; (4) performing 1H nuclear magnetic resonance detection; (5) screening differential metabolites; and (6) performing metabolism pathway analysis. The method studies influence of different cell differential metabolites and metabolic pathway by applying H-nuclear magnetic resonance technology in combination with metabonomic methodology, and the basic research provides theoretical basis for studying the method for analyzing sub-toxicity of vitamin C for RAW264.7 or K562 cells.

The invention relates to a bath or oral application of immune activate compound in the fish immunity, wherein the invention has the advantages that: said compound ISCOMs is used to bath immunity to improve the antibody level and improve the increment transformation ability of T-lymphocyte, to induce the immune protection; when in the same dosage, the antibody level is higher than non-adjuvant group and the ISM1312 group; and the ISCOMs used in oral can improve the antibody level and improve the increment transformation ability of T-lymphocyte, to induce the immune protection.

The invention provides a health product with the functions of invigorating spleen to promote digestion and eliminate stagnation, aiming at solving the problems that products on the market contain diversified and miscellaneous components and is single in function, can be taken only for infected population, have certain side effect and cannot be taken as daily prevention and health products for eating of common people. The health product provided by the invention is characterized in that each dosage of the health product contains the health and treatment ingredients according to the proportions: 38-42 parts of hericium erinaceus polysaccharide, 8-12 parts of lentinan, 8-12 parts of fermented curcuma powder, 8-12 parts of poria cocos extract, 8-12 parts of Chinese hawthorn extract, 3-7 parts of Chinese yam extract and 3-7 parts of fructus amomi powder. The finally formed dosage forms of the health product are powder, tablets or capsules. The health product is simple in compatibility, good in health effect, high in safety and reliability, free of toxic or side effect, light in flavor, good in mouthfeel and convenient to carry and is capable of being taken as a daily health product to be eaten by common people.

The invention discloses a penitrem A combined antigen as well as preparation and an application of an antibody of the antigen. The median inhibitory dose (IC50), detected by a penitrem A enzyme-linked immunosorbent assay kit, of penitrem A for a reaction between a specific antibody of the penitrem A and penitrem A coating antigens is 100 ng/mL, the lowest detection limit of penitrem A is 30 ng/mL, and the cross reaction rate of penitrem A and an aflatoxin B1 sample, the cross reaction rate of penitrem A and a cyclopiazonic acid sample, the cross reaction rate of penitrem A and a vomitoxin and the cross reaction rate of penitrem A and a citreoviridin sample are all smaller than 0.1%. The specific antibody of penitrem A in the penitrem A enzyme-linked immunosorbent assay kit has the characteristics of high potency, high sensitivity and high specificity and can be used for quickly, sensitively and easily detecting the residual amount of penitrem A in animal-origin food.

The invention belongs to the field of serum drug concentration monitoring after renal transplantation, and discloses a primer set, a kit and an evaluation method for evaluating tacrolimus metabolism.Specifically, genotypes of five SNP loci (CYP3A5 rs15524, CYP3A5 rs4646453, POR rs2286822, POR rs1135612 and POR rs1057868) on two important genes CYP3A5 and POR related to tacrolimus metabolism are detected to predict individual metabolic conditions of tacrolimus in a patient, so as to provide medication guidance for individualized design of an initial dosage of tacrolimus.

The invention discloses an application of proanthocyanidins in preparing diet food or drug, and discloses an application of a drug composition with proanthocyanidins as an active component and pharmaceutically acceptable additives in preparing the diet food or drug. Mice experiments demonstrate that proanthocyanidins has obvious reduction effects for growth rate of mice body weight, food utilization rate and body fat and presents a dose-dependent relationship, can effectively reduce blood glucose level and serum cholesterol level of the mice, and can increase serum free fatty acid level and oxidation resistant level. Novel medical application and novel application field are developed for proanthocyanidins. Experiments show that the concentration of proanthocyanidins required for treating obesity is relatively low; proanthocyanidins has no side or toxic effect and has the functions of protecting human body blood circulation, enhancing immunity and protecting eyesight, thereby guaranteeing effectiveness of weight reduction and playing a promotion effect for body health.

The invention relates to a bacterium inhibiting feed and a preparation method and application thereof. The bacterium inhibiting feed comprises a basic ration and yeast essence, wherein the content ofbeta-glucan in the yeast essence is 25-50%, and the relative molecular weight of 99% or above of the beta-glucan is 3.0*10<5>-1.0*10<6>; and the content of mannan in the yeast essence is greater thanor equal to 20%, and the relative molecular weight of 99% or above of the mannan is 8.0*10<5>-2.0*10<6>. The yeast essence related in the feed disclosed by the invention is used as a single substanceto be added in the feed, the recommendation dosage is stable, and after in vitro bacterium inhibiting zone simulation and breeding animal in vivo experiment verification, the bacterium inhibiting feedshows good antibiotic replacement effects; an efficient feasible antibiotic replacement scheme can be provided for the animal breeding trade, besides, the defects that antibiotics have drug toleranceand are remained, and current antibiotic replacement products are bad in effects and lack stability are overcome, and the bacterium inhibiting feed has considerable future prospects.

The invention relates to the technical field of probiotic preparations for resisting pathogenic bacterium infection in livestock breeding, and particularly discloses a complex probiotic preparation for resisting salmonella pullorum infection and application of the complex probiotic preparation. The complex probiotic preparation comprises bacillus subtilis, bacillus licheniformis, bacillus coagulans, bacillus amyloliquefaciens, clostridium butyricum and lactobacillus plantarum. The preparation specifically improves the body's resistance to salmonella pullorum infection, significantly improves intestinal mucosal immunity, reduces or avoids intestinal diseases, maintains intestinal microecological balance, reduces the addition of the long-term subtherapeutic dose and ultra-high dose of antibiotics for preventing and treating animal diseases in feed, and extremely has promoting significance.

The invention provides vasodilating medication as means for lowering fever when administered to humans in need of such treatment. In particular, the use of B3 vitamin substances and Nitric Oxide-donor ingredients in compositions intended for use in reducing fever is introduced. The core composition substances can be used effectively on their own. Yet, in combination with anti-pyretic substances such as Aspirin, Acetaminophen, and Ibuprofen, the present invention enables the use of reduced dosage of composing substances for achievement of desired fever reduction effect. In addition, an optional addition of sweat inducing plant extracts in any of the noted compositions leads to a synergistic effect of reducing fever by increase of both skin blood flow and perspiration.

A pharmaceutical preparation including an amino acid infusion fluid is administered to patients receiving dialysis to ameliorate nutritional status of patients. As a result, anemia can be ameliorated and the required dose of erythropoietin can be reduced in these patients. Furthermore, the serum phosphate levels can be controlled to a predetermined range and protein catabolism can be suppressed in such patients. The amino acid infusion fluid has at least one essential amino acid. The preferred amino acid composition includes at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine, wherein the ratio of essential amino acids to non-essential amino acids is 2.5 or higher.